LINC02928: A Long Intergenic Non-Protein Coding RNA as a Drug Target or Biomarker

Target Name: LINC02928

NCBI ID: G105377659

LINC02928

Other Name(s): long intergenic non-protein coding RNA 2928 | Long intergenic non-protein coding RNA 2928

LINC02928: A Long Intergenic Non-Protein Coding RNA as a Drug Target or Biomarker

LINC02928 is a long intergenic non-protein coding RNA (lncRNA) that has been identified using RNA-seq technology. This RNA has been shown to play a crucial role in regulating gene expression in various organisms, including humans. The identification of new lncRNA has the potential to uncover new drug targets or biomarkers for various diseases. In this article, we will explore the potential implications of LINC02928 as a drug target or biomarker.

Expression and Function

LINC02928 is a transcribed RNA molecule that is located between the intron and the 5' end of its host gene. It is characterized by its ability to interact with various cellular components, including RNA-proteasome complexes, and has been shown to play a role in regulating gene expression.

Several studies have demonstrated that LINC02928 is involved in the regulation of cell adhesion, a critical process that plays a crucial role in various biological processes, including tissue repair and regeneration. LINC02928 has been shown to interact with the protein known as EADN, which is involved in the regulation of cell adhesion.

Additionally, LINC02928 has been shown to play a role in the regulation of cell cycle progression. LINC02928 has been shown to interact with the protein known as p21, which is a key regulator of the T-cell receptor (TCR), a critical protein that plays a role in cell adaptation and proliferation.

Potential Drug Target

The potential drug targets for LINC02928 are vast, as it has been shown to be involved in the regulation of various cellular processes that are critical for human health. One potential drug target for LINC02928 is the regulation of cell adhesion, which is involved in various diseases, including cancer, neurodegenerative diseases, and developmental disorders.

Another potential drug target for LINC02928 is the regulation of cell cycle progression, which is involved in various diseases, including cancer, neurodegenerative diseases, and developmental disorders. LINC02928 has been shown to interact with the protein known as p21, which is a key regulator of the T-cell receptor (TCR), a critical protein that plays a role in cell adaptation and proliferation.

Biomarker

The identification of LINC02928 as a long intergenic non-protein coding RNA (lncRNA) with potential drug targets or biomarkers is significant, as it demonstrates the potential for new discoveries in the field of molecular biology. The regulation of cell adhesion and cell cycle progression are critical processes that play a crucial role in various diseases, including cancer, neurodegenerative diseases, and developmental disorders.

Conclusion

In conclusion, LINC02928 is a long intergenic non-protein coding RNA (lncRNA) that has been identified using RNA-seq technology. The regulation of cell adhesion and cell cycle progression are critical processes that play a crucial role in various diseases, including cancer, neurodegenerative diseases, and developmental disorders. The potential drug targets for LINC02928 are vast, as it has been shown to be involved in the regulation of various cellular processes that are critical for human health. Further research is needed to fully understand the role of LINC02928 as a drug target or biomarker.

Protein Name: Long Intergenic Non-protein Coding RNA 2928

The "LINC02928 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC02928 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets